skip to Main Content

Medicine Man Technologies Acquisiton Target, MedPharm, to Launch a Landmark Randomized Clinical Trial Taking Aim at Treating Alzheimer’s with Cannabis

PRESS RELEASE DENVER--(BUSINESS WIRE)--Medicine Man Technologies Acquisiton Target, MedPharm, to Launch a Landmark Randomized Clinical Trial Taking Aim at Treating Alzheimer’s with Cannabis (Graphic: Business Wire) MedPharm will be exploring the action of a research-based, scientifically formulated compound containing cannabinoids…

Read More

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease

Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative…

Read More

Classifying Medical Cannabis vs. Traditional Pharmaceuticals Guides Marketing Efforts

When considering Medical Cannabinoid Therapy (MCT), most informed physicians and patients focus on two classes of cannabinoids:  tetrahydrocannabinols (THC) and cannabidiols (CBD).  However, research has identified over 500 compounds in cannabis, including over 120 distinct cannabinoids and over 100 terpenes. Despite…

Read More

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer

Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New…

Read More

Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring

GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading. GW Pharmaceuticals GWPH, +10.22%  reported second-quarter sales of $68.4 million for Epidiolex, which uses…

Read More

Columbia Care Announces Launch of Pioneering Research Study to Identify Genetic Factors Affecting the Efficacy and Safety of Medical Cannabis

PRESS RELEASE First-of-their-kind results to enhance patient experience and efficacy of Columbia Care products by further informing and personalizing treatment recommendations to support optimal product dosing and formulation selection NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (“Columbia Care” or the “Company”) (NEO:…

Read More
Back To Top
×Close search
Search